Prescription for growth at Pfizer? Analysts say deals – Reuters


Reuters

Prescription for growth at Pfizer? Analysts say deals
Reuters
N) posted basically flat first-quarter earnings, prompting suggestions that the largest U.S. drugmaker needs to do deals in order to improve its growth prospects. Sales of rheumatoid arthritis drug Xeljanz, prostate cancer treatment Xtandi and
Pfizer’s Lackluster Sales May Fuel Speculation for DealsBloomberg

all 123 news articles »

Read More…

Share This: